Neurocrine Biosciences (BSP:N1BI34) Beginning Cash Position : R$1,388 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Beginning Cash Position?

Neurocrine Biosciences's Beginning Cash Position for the quarter that ended in Mar. 2025 was R$1,388 Mil.

Neurocrine Biosciences's quarterly Beginning Cash Position increased from Sep. 2024 (R$820 Mil) to Dec. 2024 (R$2,177 Mil) but then declined from Dec. 2024 (R$2,177 Mil) to Mar. 2025 (R$1,388 Mil).

Neurocrine Biosciences's annual Beginning Cash Position declined from Dec. 2022 (R$1,804 Mil) to Dec. 2023 (R$1,326 Mil) but then increased from Dec. 2023 (R$1,326 Mil) to Dec. 2024 (R$1,581 Mil).

Neurocrine Biosciences Beginning Cash Position Historical Data

The historical data trend for Neurocrine Biosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Beginning Cash Position Chart

Neurocrine Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

594.21

1,076.13

1,804.42

1,326.38

1,580.77

Neurocrine Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															1,290.27	2,177.60	819.59	2,176.84	1,387.70

Neurocrine Biosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Neurocrine Biosciences Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

NBIX:USA 0K6R:UK NB3:Germany

Address

6027 Edgewood Bend Court, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines